Patent US5641756A successfully refreshed from Google Patents.
US5641756A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Modified VEGF oligonucleotides
Assignee: Aceragen Inc
•
Filing: 1995-12-08
•
Granted: 1997-06-24
•
Expires: 2015-12-08
Abstract
Abstract Disclosed are oligonucleotides complementary to VEGF-specific nucleic acid useful in reducing the expression of VEGF. Also disclosed are pharmaceutical formulations containing such oligonucleotides useful for treating various disorders associated with neovascularization and angiogenesis.
Inventors
- 👤 Gregory S. Robinson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 23:09
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; C12N15/1136; A; A61; A61P; A61P17/00; A61P27/00; A61P27/02; A61P3/00; A61P3/08; A61P35/00; A61P9/00; A61P9/10; A61K; A61K38/00; C12N2310/00; C12N2310/30; C12N2310/31; C12N2310/312; C12N2310/3125; C12N2310/314; C12N2310/315; C12N2310/316; C12N2310/317; C12N2310/32; C12N2310/321; C12N2310/35; C12N2310/352; C12N2310/3521; C12N2310/50; C12N2310/53
Claims Analysis
Total Claims: 26
Claim 1
Independent Claim
70 words
A synthetic oligonucleotide complementary to a nucleic acid specific for human vascular endothelial growth factor selected from the group consisting of an oligonucleotide having SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:16.
Claim 2
Dependent Claim
70 words
A synthetic oligonucleotide complementary to a nucleic acid specific for human vascular endothelial growth factor selected from the group consisting of an oligonucleotide having SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:16.
Claim 3
Dependent Claim
10 words
The oligonucleotide of claim 1 having SEQ ID NO: 2.
Claim 4
Dependent Claim
9 words
The oligonucleotide of claim 1 having SEQ ID NO:3.
Claim 5
Dependent Claim
9 words
The oligonucleotide of claim 1 having SEQ ID NO:4.
Claim 6
Dependent Claim
9 words
The oligonucleotide of claim 1 having SEQ ID NO:5.
Claim 7
Dependent Claim
9 words
The oligonucleotide of claim 1 having SEQ ID NO:12.
Claim 8
Dependent Claim
9 words
The oligonucleotide of claim 1 having SEQ ID NO:13.
Claim 9
Dependent Claim
9 words
The oligonucleotide of claim 1 having SEQ ID NO:14.
Claim 10
Dependent Claim
9 words
The oligonucleotide of claim 1 having SEQ ID NO:15.
Claim 11
Dependent Claim
9 words
The oligonucleotide of claim 1 having SEQ ID NO:16.
Claim 12
Dependent Claim
36 words
The oligonucleotide of claim 1 having a modification selected from the group consisting of an alkylphosphonate, phosphorothioate, phosphorodithioate, phosphate ester, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, and carboxymethyl ester internucleotide linkage, and a combination thereof.
Claim 13
Dependent Claim
12 words
The oligonucleotide of claim 11 having at least one phosphorothioate internucleotide linkage.
Claim 14
Dependent Claim
9 words
The oligonucleotide of claim 12 having phosphorothioate internucleotide linkages.
Claim 15
Dependent Claim
10 words
The oligonucleotide of claim 1 consisting essentially of 2'-O-alkylated ribonucleotides.
Claim 16
Dependent Claim
12 words
The oligonucleotide of claim 1 comprising four or five 5' 2'-O-alkylated ribonucleotides.
Claim 17
Dependent Claim
12 words
The oligonucleotide of claim 1 comprising four or five 3' 2'-O-alkylated ribonucleotides.
Claim 18
Dependent Claim
12 words
The oligonucleotide of claim 15 comprising four or five 3' 2'-O-alkylated ribonucleotides.
Claim 19
Dependent Claim
12 words
The oligonucleotide of claim 12 comprising four or five 5' 2'-O-alkylated ribonucleotides.
Claim 20
Dependent Claim
24 words
A method of inhibiting VEGF production in a cell comprising the step of contacting the cell in vitro with an oligonucleotide of claim 1.
Claim 21
Dependent Claim
24 words
A method of inhibiting VEGF production in a cell comprising the step of contacting the cell in vitro with an oligonucleotide of claim 11.
Claim 22
Dependent Claim
17 words
A pharmaceutical composition comprising at least one synthetic oligonucleotide of claim 1 in a physiologically acceptable carrier.
Claim 23
Dependent Claim
17 words
A pharmaceutical composition comprising at least one synthetic oligonucleotide of claim 11 in a physiologically acceptable carrier.
Claim 24
Dependent Claim
9 words
The oligonucleotide of claim 1 having SEQ ID NO:1.
Claim 25
Dependent Claim
26 words
A method of inhibiting VEGF production in a mammal comprising the step of administering intravitreally to an eye of a mammal an oligonucleotide of claim 1.
Claim 26
Dependent Claim
26 words
A method of inhibiting VEGF production in a mammal comprising the step of administering intravitreally to an eye of a mammal an oligonucleotide of claim 11.
References Cited (Backward Citations)
WO1995004142A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-06-23 | 2000-12-23 | 2001-06-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-06-23 | 2004-12-23 | 2005-06-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-06-23 | 2008-12-23 | 2009-06-24 | $7700.00 | Window Closed / Lapsed |